679VPEfficacy of givinostat in the off-target population of EPIDYS: a subgroup analysis
C. Laverty(University of California San Diego), Richard S. Finkel(St. Jude Children's Research Hospital), P. Bettica(Italfarmaco (Italy)), S. Cazzaniga(Italfarmaco (Italy)), Federica Alessi(Policlinico Umberto I), H. Phan(Rare Disease Therapeutics (United States))
Cited by 0
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565